Brief: Mateon announces initiation of focus study in platinum-resistant ovarian cancer
23/06/2016 13:01
June 23 (Reuters) - Mateon
* Announces initiation of focus study in platinum resistant
ovarian cancer
* In second stage, which would support nda if positive, co
plans to enroll up to 356 patients without any planned interim
analyses
* Mateon therapeutics inc says focus study has two stages
* Mateon therapeutics inc says in first stage company plans
to enroll up to 80 patients
Source text for Eikon: ID:nGNXMWKWXa
Further company coverage: MATN.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas